Decreased Quality of Life in Patients with Acromegaly Despite Long-Term Cure of Growth Hormone Excess (original) (raw)
The Relationship between 24-Hour Growth Hormone Secretion and Insulin-Like Growth Factor I in Patients with Successfully Treated Acromegaly: Impact of Surgery or Radiotherapy
Stephen Shalet
The Journal of Clinical Endocrinology & Metabolism, 2001
View PDFchevron_right
Growth Hormone Deficiency Is Associated with Decreased Quality of Life in Patients with Prior Acromegaly
Zehra Omer, Tamara Wexler
The Journal of Clinical Endocrinology & Metabolism, 2009
View PDFchevron_right
Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly
Ferdinand Roelfsema
Pituitary, 2009
View PDFchevron_right
Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment
Federico Gatto
The Journal of Clinical Endocrinology & Metabolism
View PDFchevron_right
Predictors of the Outcome of Surgical Treatment in Acromegaly and the Value of the Mean Growth Hormone Day Curve in Assessing Postoperative Disease Activity
John Monson
The Journal of Clinical Endocrinology & Metabolism, 2001
View PDFchevron_right
Limited effects of growth hormone replacement in adults with growth hormone deficiency after treatment for acromegaly
Ferdinand Roelfsema
2008
View PDFchevron_right
GH deficiency in patients after cure of acromegaly by surgery alone
Hiroshi Nishioka
European Journal of Endocrinology, 2011
View PDFchevron_right
Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly
R. García-mayor
Metabolism, 1997
View PDFchevron_right
Quality of Life in Treated Patients with Acromegaly
Helene Markkanen
The Journal of Clinical Endocrinology & Metabolism, 2006
View PDFchevron_right
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Ariel Barkan
The Lancet, 2001
View PDFchevron_right
Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR®
Giselle Taboada
Growth Hormone & IGF Research, 2008
View PDFchevron_right
Pituitary Irradiation Is Ineffective in Normalizing Plasma Insulin-Like Growth Factor I in Patients with Acromegaly 1
Ariel Barkan
The Journal of Clinical Endocrinology & Metabolism, 1997
View PDFchevron_right
Plasma Insulin-Like Growth Factor-I/Somatomedin-C in Acromegaly: Correlation With the Degree of Growth Hormone Hypersecretion*
Ariel Barkan
The Journal of Clinical Endocrinology & Metabolism, 1988
View PDFchevron_right
Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR
Joyce Dias
Growth Hormone & IGF Research, 2010
View PDFchevron_right
Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly
Mikkel Andreassen
Clinical Endocrinology, 2014
View PDFchevron_right
French consensus on the management of acromegaly
Thierry Brue
Annales d'Endocrinologie, 2009
View PDFchevron_right
Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly
Enrica Ciccarelli
Acta Endocrinologica, 1989
View PDFchevron_right
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
L. Katznelson, David Clemmons
New England Journal of Medicine, 2000
View PDFchevron_right
Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study
Ulla Feldt-rasmussen
European Journal of Endocrinology, 2018
View PDFchevron_right
Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly
Katherine Morrison
Journal of Clinical …, 2006
View PDFchevron_right
Growth Hormone Rebound After Cessation of SMS 201-995 Treatment in Acromegaly
Hugues Beauregard
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1989
View PDFchevron_right
Atypical Course of a Patient With AIP-Positive Acromegaly: From GH Excess to GH Deficiency and Back to GH Excess
Amayrani Cano Zaragoza
JCEM Case Reports
View PDFchevron_right
Determinants of Survival in Treated Acromegaly in a Single Center: Predictive Value of Serial Insulin-Like Growth Factor I Measurements
Ferdinand Roelfsema
View PDFchevron_right
Medical Consequences of Long-term Treatment of Acromegaly
Mariano Galdiero
European Endocrinology, 2010
View PDFchevron_right
Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm
David Clemmons
The Journal of Clinical Endocrinology & Metabolism, 2003
View PDFchevron_right
GH Replacement Improves Quality of Life and Metabolic Parameters in Cured Acromegalic Patients with Growth Hormone Deficiency
Silvia Bergamaschi
The Journal of Clinical Endocrinology & Metabolism, 2012
View PDFchevron_right